2023
DOI: 10.1007/s11886-023-01843-4
|View full text |Cite
|
Sign up to set email alerts
|

Review of Pathophysiology of Cardiogenic Shock and Escalation of Mechanical Circulatory Support Devices

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 68 publications
0
2
0
Order By: Relevance
“…The prevalence of CS ranges between 4%-10% [2,3,16]. Despite the current advances in multilevel treatment approaches, CS continues to entail an unacceptable early and long-term mortality risk [17], which has not changed over the last decade [18]. Presently, coronary revascularization in the acute phase of CS related to AMI has been shown as the only factor modifying prognosis positively [19].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The prevalence of CS ranges between 4%-10% [2,3,16]. Despite the current advances in multilevel treatment approaches, CS continues to entail an unacceptable early and long-term mortality risk [17], which has not changed over the last decade [18]. Presently, coronary revascularization in the acute phase of CS related to AMI has been shown as the only factor modifying prognosis positively [19].…”
Section: Discussionmentioning
confidence: 99%
“…Thus, several MCS devices have been developed aiming to break the circle and change the unfavorable prognosis in CS complicated by AMI. Furthermore, apart from augmentation of CO with the subsequent improvement of systemic perfusion, MCS can also reduce the burden of myocardial ischemia [32]. However, it is challenging to determine the appropriate time to escalate therapy to an MCS device or determine which MCS device should be used.…”
Section: Discussionmentioning
confidence: 99%